Characteristics | Entire cohort (n=267) |
Age (mean in years (SD)) | 41 (16) |
Female (n (%)) | 156 (58.4) |
Body mass index (mean in kg (SD)) | 80 (21) |
Time on infliximab (median in months (IQR)) | 14 (8–34) |
Combination therapy with an immunomodulator (n (%)) | 144 (53.9) |
On methotrexate (n (%)) | 36 (21.6) |
On a thiopurine (n (%)) | 108 (40.4) |
IBD subtype | |
CD | 190 (71.2) |
UC | 77 (28.8) |
CD phenotype | |
Luminal/inflammatory (n (%)) | 49 (18.4) |
Structuring (n (%)) | 125 (65.3) |
Penetrating (n (%)) | 90 (47.4) |
Perianal disease (n (%)) | 64 (33.7) |
CD location | |
Ileal only (n (%)) | 20 (10.5) |
Colonic only (n (%)) | 39 (20.5) |
Ileocolonic (n (%)) | 127 (66.8) |
UC location | |
Ulcerative proctitis (n (%)) | 2 (2.6) |
Left-sided colitis (n (%)) | 19 (24.7) |
Pancolitis (n (%)) | 56 (72.7) |
CD, Crohn’s disease; IBD, inflammatory bowel disease; UC, ulcerative colitis.